Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Epidemiologic and genomewide association studies have linked loss-of-function variants in ANGPTL3, encoding angiopoietin-like 3, with low levels of plasma lipoproteins. METHODS: We evaluated antisense oligonucleotides (ASOs) targeting Angptl3 messenger RNA (mRNA) for effects on plasma lipid levels, triglyceride clearance, liver triglyceride content, insulin sensitivity, and atherosclerosis in mice. Subsequently, 44 human participants (with triglyceride levels of either 90 to 150 mg per deciliter [1.0 to 1.7 mmol per liter] or >150 mg per deciliter, depending on the dose group) were randomly assigned to receive subcutaneous injections of placebo or an antisense oligonucleotide targeting ANGPTL3 mRNA in a single dose (20, 40, or 80 mg) or multiple doses (10, 20, 40, or 60 mg per week for 6 weeks). The main end points were safety, side-effect profile, pharmacokinetic and pharmacodynamic measures, and changes in levels of lipids and lipoproteins. RESULTS: The treated mice had dose-dependent reductions in levels of hepatic Angptl3 mRNA, Angptl3 protein, triglycerides, and low-density lipoprotein (LDL) cholesterol, as well as reductions in liver triglyceride content and atherosclerosis progression and increases in insulin sensitivity. After 6 weeks of treatment, persons in the multiple-dose groups had reductions in levels of ANGPTL3 protein (reductions of 46.6 to 84.5% from baseline, P<0.01 for all doses vs. placebo) and in levels of triglycerides (reductions of 33.2 to 63.1%), LDL cholesterol (1.3 to 32.9%), very-low-density lipoprotein cholesterol (27.9 to 60.0%), non-high-density lipoprotein cholesterol (10.0 to 36.6%), apolipoprotein B (3.4 to 25.7%), and apolipoprotein C-III (18.9 to 58.8%). Three participants who received the antisense oligonucleotide and three who received placebo reported dizziness or headache. There were no serious adverse events. CONCLUSIONS: Oligonucleotides targeting mouse Angptl3 retarded the progression of atherosclerosis and reduced levels of atherogenic lipoproteins in mice. Use of the same strategy to target human ANGPTL3 reduced levels of atherogenic lipoproteins in humans. (Funded by Ionis Pharmaceuticals; ClinicalTrials.gov number, NCT02709850 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, the LDL-C lowering effects of ANGPTL3 inhibition with either monoclonal antibodies or antisense oligonucleotides seems to be LDL receptor (LDLR) independent since marked LDL-C lowering is observed in both Ldlr knock-out (KO) mice6,8 and patients with homozygous familial hypercholesterolemia (hoFH).9”
In the citing paper
“Interestingly, the LDL-C lowering effects of ANGPTL3 inhibition with either monoclonal antibodies or antisense oligonucleotides seems to be LDL receptor (LDLR) independent since marked LDL-C lowering is observed in both Ldlr knock-out (KO) mice6,8 and patients with homozygous familial hypercholesterolemia (hoFH).9”
In the citing paper
“A decrease in VLDL-TG secretion, but not in VLDL apoB secretion or VLDL clearance, was observed in mouse models treated with a monoclonal antibody6 or antisense oligonucleotides8 against ANGPTL3.”
In the citing paper
“In initial studies, treatment with Vupanorsen was associated with a 33%–63% decrease in triglycerides as well as reductions in Apo-C III, remnant and total cholesterol, HDL-C, and LDL-C (169).”
From Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8 (2021) · cites this paper as [169]
In the citing paper
“In a dose-finding study in HTG patients, IONIS-ANGPTL3-LRx reduced TG and LDL-C by up to 63.1% and 32.9%, respectively.82”
From Clinical review on triglycerides (2020) · cites this paper as [82]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Exome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002926 · Cited by 754
Viney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31009-1 · Cited by 754
Self-citationAntisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Self-citationInactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
Dewey, F. E., Gusarova, V., O’Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C. V., Habegger, L., Buckler, D., Lai, K.-M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510926 · Cited by 497
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease
Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507652 · Cited by 493
Targeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491
Self-citationWallace, C., Newhouse, S. J., Braund, P., Zhang, F., Tobin, M., Falchi, M., Ahmadi, K., Dobson, R. J., Marçano, A. C. B., Hajat, C., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2007.11.001 · Cited by 439
Research works printed but not linked: 1
- Romeo S, 2009, J Clin Invest, 119, 70
Cited by
Items 201–300 of 575
Kosmas, C. E., Bousvarou, M. D., Sourlas, A., Papakonstantinou, E. J., Peña Genao, E., Echavarria Uceta, R., & Guzman, E. (2022) · Clinical Pharmacology: Advances and Applications · doi:10.2147/cpaa.s345072 · Cited by 34
Zhang, Y., Yan, C., Dong, Y., Zhao, J., Yang, X., Deng, Y., Su, L., Yin, J., Zhang, Y., Sun, F., et al. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.05.011 · Cited by 37
Reece, A. S., Wang, W., & Hulse, G. K. (2018) · Medical Hypotheses · doi:10.1016/j.mehy.2018.04.011 · Cited by 35
Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a)
Waldmann, E., & Parhofer, K. G. (2019) · Pathology · doi:10.1016/j.pathol.2018.10.016 · Cited by 35
Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.964 · Cited by 39
Moving Targets: Recent Advances in Lipid-Lowering Therapies
Larsen, L. E., Stoekenbroek, R. M., Kastelein, J. J. P., & Holleboom, A. G. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.312028 · Cited by 39
Gene-based therapy in lipid management: the winding road from promise to practice
Tromp, T. R., Stroes, E. S. G., & Hovingh, G. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1757070 · Cited by 34
Nakamura, A., Ali, S. A., & Kapoor, M. (2020) · Bone · doi:10.1016/j.bone.2020.115461 · Cited by 36
Thambiah, S. C., & Lai, L. C. (2021) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2021.e00248 · Cited by 51
Zuo, Y., Zhang, C., Zhou, Y., Li, H., Xiao, W., Herzog, R. W., Xu, J., Zhang, J., Chen, Y. E., & Han, R. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01036-0 · Cited by 34
LncRNA EILA promotes CDK4/6 inhibitor resistance in breast cancer by stabilizing cyclin E1 protein
Cai, Z., Shi, Q., Li, Y., Jin, L., Li, S., Wong, L. L., Wang, J., Jiang, X., Zhu, M., Lin, J., et al. (2023) · Science Advances · doi:10.1126/sciadv.adi3821 · Cited by 35
Coronary heart disease risk associated with the dyslipidaemia of chronic kidney disease
Lamprea-Montealegre, J. A., McClelland, R. L., Grams, M. E., Ouyang, P., Szklo, M., & de Boer, I. H. (2018) · Heart · doi:10.1136/heartjnl-2017-312794 · Cited by 33
Klarin, D. M., Cambria, R. P., Ergul, E. A., Silverman, S. B., Patel, V. I., LaMuraglia, G. M., Conrad, M. F., & Clouse, W. D. (2018) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2018.01.064 · Cited by 33
Yang, J. X., Song, Q., Niu, S., Chen, H., Petersen, R. B., Zhang, Y., & Huang, K. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30534 · Cited by 35
Kristensen, K. K., Leth-Espensen, K. Z., Kumari, A., Grønnemose, A. L., Winther, A.-M. L., Young, S. G., & Ploug, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.702508 · Cited by 35
RNA Silencing in the Management of Dyslipidemias
Henney, N. C., Banach, M., & Penson, P. E. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00968-7 · Cited by 32
Dawn of Epitranscriptomic Medicine
Gatsiou, A., & Stellos, K. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.001927 · Cited by 32
Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition
Musunuru, K. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-044918 · Cited by 34
Silbernagel, G., Chen, Y., Li, H., Lemen, D., Wen, Y., Zhen, Y., Rief, M., Kleber, M. E., Delgado, G., Sarzynski, M. A., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.069272 · Cited by 35
Can targeting ANGPTL proteins improve glucose tolerance?
Davies, B. S. J. (2018) · Diabetologia · doi:10.1007/s00125-018-4604-4 · Cited by 31
New and emerging lipid-modifying drugs to lower LDL cholesterol
Kosmas, C. E., Pantou, D., Sourlas, A., Papakonstantinou, E. J., Uceta, R. E., & Guzman, E. (2021) · Drugs in Context · doi:10.7573/dic.2021-8-3 · Cited by 35
Foss‐Freitas, M. C., Akıncı, B., Neidert, A., Bartlett, V. J., Hurh, E., Karwatowska‐Prokopczuk, E., & Oral, E. A. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01589-4 · Cited by 32
Self-citationYeoh, Y. Q., Amin, A., Cuic, B., Tomas, D., Turner, B. J., & Shabanpoor, F. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116737 · Cited by 35
Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia
Mohamed, F., Botha, T. C., & Raal, F. J. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000755 · Cited by 29
RNA-based therapy in the management of lipid disorders: a review
Blom, D. J., Marais, A. D., Moodley, R., van der Merwe, N., van Tonder, A., & Raal, F. J. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01649-3 · Cited by 31
Deng, M., Kutrolli, E., Sadewasser, A., Michel, S., Joibari, M. M., Jaschinski, F., Olivecrona, G., Nilsson, S. K., & Kersten, S. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100237 · Cited by 31
The promising novel therapies for familial hypercholesterolemia
Chen, R., Lin, S., & Chen, X. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24552 · Cited by 32
Vaillant, A. (2022) · Viruses · doi:10.3390/v14092052 · Cited by 33
A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in mice
Fowler, A., Sampson, M. L., Remaley, A. T., & Chackerian, B. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.077 · Cited by 29
Regulation of angiopoietin-like 4 and lipoprotein lipase in human adipose tissue
Dijk, W., Schutte, S., Aarts, E. O., Janssen, I. M. C., Afman, L. A., & Kersten, S. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.02.006 · Cited by 30
Genome-Wide Association Studies of Coronary Artery Disease: Recent Progress and Challenges Ahead
Clarke, S. L., & Assimes, T. L. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0748-4 · Cited by 28
Lumpers and splitters: the bumpy road to precision medicine
Lüscher, T. F. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz644 · Cited by 27
Advancements in the Treatment of Homozygous Familial Hypercholesterolemia
Bajaj, A., & Cuchel, M. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17065 · Cited by 31
Angiopoietin-Like 3 Protein Inhibition: A New Frontier in Lipid-Lowering Treatment
Lang, W. R., & Frishman, W. H. (2019) · Cardiology in Review · doi:10.1097/crd.0000000000000258 · Cited by 29
New approaches to triglyceride reduction: is there any hope left?
Filtz, A., Parihar, S., Greenberg, G. S., Park, C. M., Scotti, A., Lorenzatti, D., Badimon, J. J., Soffer, D. E., Toth, P. P., Lavie, C. J., et al. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100648 · Cited by 26
“…phase 1 and 2a trials in subjects with HTG, type 2 diabetes mellitus, and nonalcoholic fatty liver disease, the phase 2b trial, Effect of vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol (TRANSLATE-TIMI 70) was conducted [145,146].”
BackgroundYang, H. J., Xiao, L., & Xu, D. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07001-0 · Cited by 26
Emerging Anti-Atherosclerotic Therapies
Gluba-Brzózka, A., Franczyk, B., Rysz-Górzyńska, M., Ławiński, J., & Rysz, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212109 · Cited by 30
Benichou, S. A., Jauvin, D., Serres‐Bérard, T. D., Bennett, F., Rigo, F., Gourdon, G., Boutjdir, M., Chahine, M., & Puymirat, J. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.069 · Cited by 30
GALNT2 regulates ANGPTL3 cleavage in cells and in vivo of mice
Li, X., Zhang, Y., Zhang, M., & Wang, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-73388-3 · Cited by 26
Novel RNAi-Based Therapies for Atherosclerosis
Ruotsalainen, A., Mäkinen, P. I., & Ylä‐Herttuala, S. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00938-z · Cited by 27
D’Erasmo, L., Bini, S., & Arca, M. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00967-8 · Cited by 28
Increasing Lipolysis and Reducing Atherosclerosis
Tall, A. R. (2017) · New England Journal of Medicine · doi:10.1056/nejme1706907 · Cited by 26
Managing dyslipidemia in patients with Type 2 diabetes
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1912734 · Cited by 32
Austin, T. R., McHugh, C., Brody, J. A., Bis, J. C., Sitlani, C. M., Bartz, T. M., Biggs, M. L., Bansal, N., Bůžková, P., Carr, S. A., et al. (2022) · European Journal of Epidemiology · doi:10.1007/s10654-022-00888-z · Cited by 26
Nonviral Delivery of CRISPR/Cas Systems in mRNA Format
Liu, Z., Li, Z., & Li, B. (2022) · Advanced NanoBiomed Research · doi:10.1002/anbr.202200082 · Cited by 28
Current Treatment Options in Homozygous Familial Hypercholesterolemia
Kayıkçıoğlu, M., & Tokgözoğlu, L. S. (2022) · Pharmaceuticals · doi:10.3390/ph16010064 · Cited by 26
Drug development advances in human genetics‐based targets
Zhang, X., Yu, W., Li, Y., Wang, A., Cao, H., & Fu, Y. (2024) · MedComm · doi:10.1002/mco2.481 · Cited by 31
New Therapeutic Approaches for Familial Hypercholesterolemia
Ajufo, E., & Rader, D. J. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-051215-030943 · Cited by 26
Khoury, É., Brisson, D., Roy, N., Tremblay, G., & Gaudet, D. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1602606 · Cited by 31
The Role of RNA-Targeted Therapeutics to Reduce ASCVD Risk: What Have We Learned Recently?
Miname, M. H., Rocha, V. Z., & Santos, R. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00936-1 · Cited by 26
Chen, P., Chao, T.-Y., Hsu, H., Wang, C., Lin, C.-Y., Gao, W.-Y., Wu, M., & Yen, J.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189853 · Cited by 27
Monocyte and macrophage foam cells in diabetes-accelerated atherosclerosis
Cervantes, J., & Kanter, J. E. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1213177 · Cited by 27
Liu, Y., Lu, K., Zhang, R., Hu, D., Yang, Z., Zeng, J., & Cai, W. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00574 · Cited by 29
In vivo base editing of Angptl3 via lipid nanoparticles to treat cardiovascular disease
Khirallah, J., Bloomer, H., Wich, D., Huang, C., Workman, J. N., Li, Y., Newby, G. A., Liu, D. R., & Xu, Q. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102486 · Cited by 30
Li, W., Yin, R., Cao, X., Chen, W., Huang, F., & Wu, J. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0677-9 · Cited by 27
Kypreos, K. E., Bitzur, R., Karavia, E. A., Xepapadaki, E., Panayiotakopoulos, G. D., & Constantinou, C. (2018) · Angiology · doi:10.1177/0003319718779533 · Cited by 29
Wu, Y., Yang, J., Liu, X., Zhang, Y., Lei, A., Yi, R., Tan, F., & Zhao, X. (2020) · Food Science & Nutrition · doi:10.1002/fsn3.1758 · Cited by 24
Friend or foe for obesity: How hepatokines remodel adipose tissues and translational perspective
Zhang, Y., Wang, Y., & Liu, J. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2021.12.011 · Cited by 33
Vahdat‐Lasemi, F., Mahjoubin‐Tehran, M., Aghaee‐Bakhtiari, S. H., Jalili, A., Jaafari, M. R., & Sahebkar, A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.04.007 · Cited by 24
Best Treatment Strategies With Statins to Maximize the Cardiometabolic Benefits
Cho, K. I., Sakuma, I., Sohn, I. S., Hayashi, T., Shimada, K., & Koh, K. K. (2018) · Circulation Journal · doi:10.1253/circj.cj-17-1445 · Cited by 25
Emerging lipid lowering agents targeting LDL cholesterol
Wójcik, C. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1751422 · Cited by 23
May, L. T., Bartolo, B. A. D., Harrison, D. G., Guzik, T. J., Drummond, G. R., Figtree, G. A., Ritchie, R. H., Rye, K., & de Haan, J. B. (2022) · Clinical Science · doi:10.1042/cs20210862 · Cited by 24
New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3
Kim, J. Y., & Kim, N. H. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.1.23 · Cited by 23
ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
Chan, D. C., & Watts, G. F. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000920 · Cited by 24
Musunuru, K., & Kathiresan, S. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.88 · Cited by 23
Luo, F., Wu, P., Chen, J., Guo, Y., Wang, J., Li, X., & Fang, Z. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0835-0 · Cited by 23
Chang, C. L. (2019) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000536 · Cited by 23
Pragmatic Analysis of Dyslipidemia Involvement in Coronary Artery Disease: A Narrative Review
Mihăilă, R. G. (2020) · Current Cardiology Reviews · doi:10.2174/1573403x15666190522100041 · Cited by 29
The endocrine role of hepatokines: implications for human health and disease
Iglesias, P. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1663353 · Cited by 25
Metabolism of Triglyceride-Rich Lipoproteins
Borén, J., & Taskinen, M. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_520 · Cited by 29
Hu, X., Fan, J., Ma, Q., Han, L., Cao, Z., Xu, C., Luan, J., Jing, G., Nan, Y., Wu, T., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01456-z · Cited by 23
Recent advances in novel therapies for lipid disorders
Tirronen, A., Hokkanen, K., Vuorio, T., & Ylä‐Herttuala, S. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz132 · Cited by 22
Abidor, E., Achkar, M. A., Saidi, I. A., Lather, T., Jdaidani, J., Agarwal, A., & El‐Sayegh, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020643 · Cited by 26
Emerging drugs for the treatment of hypercholesterolemia
Bove, M., Cicero, A. F. G., & Borghi, C. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1591372 · Cited by 21
Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome
Cefalu, A. B., Giammanco, A., Noto, D., Spina, R., Cabibi, D., Barbagallo, C. M., & Averna, M. R. (2020) · Endocrine · doi:10.1007/s12020-020-02506-y · Cited by 21
New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia
Cesaro, A., Fimiani, F., Gragnano, F., Moscarella, E., Schiavo, A., Vergara, A., Akioyamen, L. E., D’Erasmo, L., Averna, M. R., Arca, M., et al. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.07.008 · Cited by 23
Angiopoietin-like 3: An important protein in regulating lipoprotein levels
Burks, K. H., Basu, D., Goldberg, I. J., & Stitziel, N. O. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101688 · Cited by 23
Arsenault, B. J., Perrot, N., & Puri, R. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1110 · Cited by 21
Towards more specific treatment for diabetic dyslipidemia
Rodriguez, V., Newman, J. D., & Schwartzbard, A. Z. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000528 · Cited by 23
Sathiyakumar, V., Pallazola, V. A., Park, J., Vakil, R. M., Toth, P. P., Lazo, M., Quispe, R., Güallar, E., Banach, M., Blumenthal, R. S., et al. (2019) · Archives of Medical Science · doi:10.5114/aoms.2019.86964 · Cited by 23
Ali, L., Cupido, A. J., Rijkers, M., Hovingh, G. K., Holleboom, A. G., Dallinga‐Thie, G. M., Stroes, E. S. G., & van den Boogert, M. A. W. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.07.001 · Cited by 23
Efficacy and Safety of Evinacumab for the Treatment of Hypercholesterolemia: A Meta-Analysis
Jin, M., Meng, F., Yang, W., Liang, L., Wang, H., & Zhenyan, F. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001073 · Cited by 22
Current pharmacotherapies for atherosclerotic cardiovascular diseases
Park, J., & Oh, G. T. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01116-1 · Cited by 22
Trafficking of Mononuclear Phagocytes in Healthy Arteries and Atherosclerosis
Tomas, L., Prica, F., & Schulz, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.718432 · Cited by 23
Sun, L., Wolska, A. T., Amar, M. J., Zubirán, R., & Remaley, A. T. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad153 · Cited by 27
Poller, W., Sahoo, S., Hajjar, R., Landmesser, U., & Krichevsky, A. M. (2023) · Cells · doi:10.3390/cells12222660 · Cited by 17
The role of remnant cholesterol in patients with ST-segment elevation myocardial infarction
Zhou, Y., Madsen, J. M., Özbek, B. T., Køber, L., Bang, L. E., Lønborg, J. T., & Engstrøm, T. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae102 · Cited by 20
Molecular aspects of hypercholesterolemia treatment: current perspectives and hopes
Ahangari, N., Ghayour‐Mobarhan, M., Sahebkar, A., & Pasdar, A. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1457795 · Cited by 24
Butler, A. A., Graham, J. L., Stanhope, K. L., Wong, S. C., King, S. M., Bremer, A. A., Krauss, R. M., Hamilton, J., & Havel, P. J. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra119000423 · Cited by 20
Genetic Analysis for Coronary Artery Disease Toward Diverse Populations
Miyazawa, K., & Ito, K. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.766485 · Cited by 21
Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk
Rikhi, R. R., & Shapiro, M. D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154611 · Cited by 19
ANGPTL3: a therapeutic target for atherosclerosis
Lim, G. B. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.91 · Cited by 19
New approaches to address dyslipidemia
Parhofer, K. G. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000456 · Cited by 20
Jiang, L., Wang, L., & Cheng, X. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.43372 · Cited by 25
Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy
Reiner, Ž. (2018) · Korean Circulation Journal · doi:10.4070/kcj.2018.0343 · Cited by 21
Surma, S., Romańczyk, M., & Filipiak, K. J. (2023) · Cardiology Journal · doi:10.5603/cj.a2021.0006 · Cited by 21
Bell, T. A., Liu, M., Donner, A. J., Lee, R. G., Mullick, A. E., & Crooke, R. M. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100101 · Cited by 21
Self-citationStroke Genetics: Turning Discoveries into Clinical Applications
Dichgans, M., Beaufort, N., Debette, S., & Anderson, C. D. (2021) · Stroke · doi:10.1161/strokeaha.121.032616 · Cited by 21
Al-Awar, A., & Hussain, S. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2911398 · Cited by 22
Wang, J., Zheng, W., Zheng, S., Yuan, Y., Wen, W., Cui, W., Xue, L., Sun, X., Shang, H., Zhang, H., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.11.023 · Cited by 20
Metadata
- Authors
- Graham, M. J., Lee, R. G., Brandt, T. A., Tai, L.-J., Fu, W., Peralta, R., Yu, R., Hurh, E., Paz, E., McEvoy, B. W., Baker, B. F., Pham, N. C., Digenio, A., Hughes, S. G., Geary, R. S., Witztum, J. L., Crooke, R. M., & Tsimikas, S.
- Affiliations
- Ionis Pharmaceuticals (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-07-20
- Volume
- 377
- Issue
- 3
- Pages
- 222-232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2618984243
- Cited by
- 573
- References
- 23
- Citations by year
- 2026: 20 · 2025: 36 · 2024: 48 · 2023: 51 · 2022: 85 · 2021: 86 · 2020: 90 · 2019: 59 · 2018: 72 · 2017: 26
- FWCI
- 52.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- ANGPTL3, antisense oligonucleotides, triglyceride lowering, hypertriglyceridemia, LDL cholesterol, hepatic triglyceride content, atherosclerosis, insulin sensitivity, lipoproteins, apolipoprotein B, apolipoprotein C-III, loss-of-function mutations, pharmacokinetics
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Adult, Aged, Animals, Coronary Artery Disease, Disease Models, Animal, Double-Blind Method, Female, Humans, Lipids, Male, Mice, Inbred Strains, Middle Aged, Oligonucleotides, RNA, Messenger, Oligonucleotides, Antisense, Angiopoietins, Dyslipidemias, Atherosclerosis, Lipid Metabolism, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.